This article is more than 5 years old. Information may no longer be current.

Glaucoma shunt shows early success in phase 2 studies

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW YORK — A shunt being developed for glaucoma patients is showing success in clinical studies, according to one surgeon.

Reay H. Brown, MD, presented phase 2 results of a bidirectional glaucoma tube-shunt. The device, called the EyePass, is being developed by GMP Co., manufacturers of cardiac care products.

Dr. Brown discussed the shunt here at the Ocular Surgery News Symposium on Cataract, Glaucoma and Refractive Surgery. He said the shunt has been implanted in 28 patients, and none has been removed after 12 months follow-up.

The EyePass “did not show erosion, migration, hypotony, choroidals or inflammation caused by other tubes,” Dr. Brown said.